Association of complementation group and mutation type with clinical outcome in Fanconi anemia

Laurence Faivre, Philippe Guardiola, Cathryn Lewis, Inderjeet Dokal, Wolfram Ebell, Ariana Zatterale, Cigdem Altay, Janet Poole, David Stones, Mei Lan Kwee, Margreet Van Weel-Sipman, Charmaine Havenga, Neil Morgan, Johan De Winter, Martin Digweed, Anna Savoia, Jan Pronk, Thomas De Ravel, Stander Jansen, Hans Joenje & 2 others Eliane Gluckman, Christopher G. Mathew

Research output: Contribution to journalArticle

157 Citations (Scopus)

Abstract

Fanconi anemia (FA) is a clinically and genetically heterogeneous disorder. Clinical care is complicated by variable age at onset and severity of hematologic symptoms. Recent advances in the molecular biology of FA have allowed us to investigate the relationship between FA genotype and the nature and severity of the clinical phenotype. Two hundred forty-five patients from all 7 known complementation groups (FA-A to FA-G) were studied. Mutations were detected in one of the cloned FANC genes in 169 patients; in the remainder the complementation group was assigned by cell fusion or Western blotting. A range of qualitative and quantitative clinical parameters was compared for each complementation group and for different classes of mutation. Significant phenotypic differences were found. FA-G patients had more severe cytopenia and a higher incidence of leukemia. Somatic abnormalities were less prevalent in FA-C, but more common in the rare groups FA-D, FA-E, and FA-F. In FA-A, patients homozygous for null mutations had an earlier onset of anemia and a higher incidence of leukemia than those with mutations producing an altered protein. In FA-C, there was a later age of onset of aplastic anemia and fewer somatic abnormalities in patients with the 322delG mutation, but there were more somatic abnormalities in patients with 1VS4 + 4A → T. This study indicates that FA patients with mutations in the FANCG gene and patients homozygous for null mutations in FANCA are high-risk groups with a poor hematologic outcome and should be considered as candidates both for frequent monitoring and early therapeutic intervention.

Original languageEnglish
Pages (from-to)4064-4070
Number of pages7
JournalBlood
Volume96
Issue number13
Publication statusPublished - 2000

Fingerprint

Fanconi Anemia
Genes
Mutation
Molecular biology
Fusion reactions
Monitoring
Proteins
Age of Onset
Leukemia
Aplastic Anemia
Cell Fusion
Incidence
Anemia
Molecular Biology

ASJC Scopus subject areas

  • Hematology

Cite this

Faivre, L., Guardiola, P., Lewis, C., Dokal, I., Ebell, W., Zatterale, A., ... Mathew, C. G. (2000). Association of complementation group and mutation type with clinical outcome in Fanconi anemia. Blood, 96(13), 4064-4070.

Association of complementation group and mutation type with clinical outcome in Fanconi anemia. / Faivre, Laurence; Guardiola, Philippe; Lewis, Cathryn; Dokal, Inderjeet; Ebell, Wolfram; Zatterale, Ariana; Altay, Cigdem; Poole, Janet; Stones, David; Kwee, Mei Lan; Van Weel-Sipman, Margreet; Havenga, Charmaine; Morgan, Neil; De Winter, Johan; Digweed, Martin; Savoia, Anna; Pronk, Jan; De Ravel, Thomas; Jansen, Stander; Joenje, Hans; Gluckman, Eliane; Mathew, Christopher G.

In: Blood, Vol. 96, No. 13, 2000, p. 4064-4070.

Research output: Contribution to journalArticle

Faivre, L, Guardiola, P, Lewis, C, Dokal, I, Ebell, W, Zatterale, A, Altay, C, Poole, J, Stones, D, Kwee, ML, Van Weel-Sipman, M, Havenga, C, Morgan, N, De Winter, J, Digweed, M, Savoia, A, Pronk, J, De Ravel, T, Jansen, S, Joenje, H, Gluckman, E & Mathew, CG 2000, 'Association of complementation group and mutation type with clinical outcome in Fanconi anemia', Blood, vol. 96, no. 13, pp. 4064-4070.
Faivre L, Guardiola P, Lewis C, Dokal I, Ebell W, Zatterale A et al. Association of complementation group and mutation type with clinical outcome in Fanconi anemia. Blood. 2000;96(13):4064-4070.
Faivre, Laurence ; Guardiola, Philippe ; Lewis, Cathryn ; Dokal, Inderjeet ; Ebell, Wolfram ; Zatterale, Ariana ; Altay, Cigdem ; Poole, Janet ; Stones, David ; Kwee, Mei Lan ; Van Weel-Sipman, Margreet ; Havenga, Charmaine ; Morgan, Neil ; De Winter, Johan ; Digweed, Martin ; Savoia, Anna ; Pronk, Jan ; De Ravel, Thomas ; Jansen, Stander ; Joenje, Hans ; Gluckman, Eliane ; Mathew, Christopher G. / Association of complementation group and mutation type with clinical outcome in Fanconi anemia. In: Blood. 2000 ; Vol. 96, No. 13. pp. 4064-4070.
@article{2b1a9208788c4c0594f20d6a702aa286,
title = "Association of complementation group and mutation type with clinical outcome in Fanconi anemia",
abstract = "Fanconi anemia (FA) is a clinically and genetically heterogeneous disorder. Clinical care is complicated by variable age at onset and severity of hematologic symptoms. Recent advances in the molecular biology of FA have allowed us to investigate the relationship between FA genotype and the nature and severity of the clinical phenotype. Two hundred forty-five patients from all 7 known complementation groups (FA-A to FA-G) were studied. Mutations were detected in one of the cloned FANC genes in 169 patients; in the remainder the complementation group was assigned by cell fusion or Western blotting. A range of qualitative and quantitative clinical parameters was compared for each complementation group and for different classes of mutation. Significant phenotypic differences were found. FA-G patients had more severe cytopenia and a higher incidence of leukemia. Somatic abnormalities were less prevalent in FA-C, but more common in the rare groups FA-D, FA-E, and FA-F. In FA-A, patients homozygous for null mutations had an earlier onset of anemia and a higher incidence of leukemia than those with mutations producing an altered protein. In FA-C, there was a later age of onset of aplastic anemia and fewer somatic abnormalities in patients with the 322delG mutation, but there were more somatic abnormalities in patients with 1VS4 + 4A → T. This study indicates that FA patients with mutations in the FANCG gene and patients homozygous for null mutations in FANCA are high-risk groups with a poor hematologic outcome and should be considered as candidates both for frequent monitoring and early therapeutic intervention.",
author = "Laurence Faivre and Philippe Guardiola and Cathryn Lewis and Inderjeet Dokal and Wolfram Ebell and Ariana Zatterale and Cigdem Altay and Janet Poole and David Stones and Kwee, {Mei Lan} and {Van Weel-Sipman}, Margreet and Charmaine Havenga and Neil Morgan and {De Winter}, Johan and Martin Digweed and Anna Savoia and Jan Pronk and {De Ravel}, Thomas and Stander Jansen and Hans Joenje and Eliane Gluckman and Mathew, {Christopher G.}",
year = "2000",
language = "English",
volume = "96",
pages = "4064--4070",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "13",

}

TY - JOUR

T1 - Association of complementation group and mutation type with clinical outcome in Fanconi anemia

AU - Faivre, Laurence

AU - Guardiola, Philippe

AU - Lewis, Cathryn

AU - Dokal, Inderjeet

AU - Ebell, Wolfram

AU - Zatterale, Ariana

AU - Altay, Cigdem

AU - Poole, Janet

AU - Stones, David

AU - Kwee, Mei Lan

AU - Van Weel-Sipman, Margreet

AU - Havenga, Charmaine

AU - Morgan, Neil

AU - De Winter, Johan

AU - Digweed, Martin

AU - Savoia, Anna

AU - Pronk, Jan

AU - De Ravel, Thomas

AU - Jansen, Stander

AU - Joenje, Hans

AU - Gluckman, Eliane

AU - Mathew, Christopher G.

PY - 2000

Y1 - 2000

N2 - Fanconi anemia (FA) is a clinically and genetically heterogeneous disorder. Clinical care is complicated by variable age at onset and severity of hematologic symptoms. Recent advances in the molecular biology of FA have allowed us to investigate the relationship between FA genotype and the nature and severity of the clinical phenotype. Two hundred forty-five patients from all 7 known complementation groups (FA-A to FA-G) were studied. Mutations were detected in one of the cloned FANC genes in 169 patients; in the remainder the complementation group was assigned by cell fusion or Western blotting. A range of qualitative and quantitative clinical parameters was compared for each complementation group and for different classes of mutation. Significant phenotypic differences were found. FA-G patients had more severe cytopenia and a higher incidence of leukemia. Somatic abnormalities were less prevalent in FA-C, but more common in the rare groups FA-D, FA-E, and FA-F. In FA-A, patients homozygous for null mutations had an earlier onset of anemia and a higher incidence of leukemia than those with mutations producing an altered protein. In FA-C, there was a later age of onset of aplastic anemia and fewer somatic abnormalities in patients with the 322delG mutation, but there were more somatic abnormalities in patients with 1VS4 + 4A → T. This study indicates that FA patients with mutations in the FANCG gene and patients homozygous for null mutations in FANCA are high-risk groups with a poor hematologic outcome and should be considered as candidates both for frequent monitoring and early therapeutic intervention.

AB - Fanconi anemia (FA) is a clinically and genetically heterogeneous disorder. Clinical care is complicated by variable age at onset and severity of hematologic symptoms. Recent advances in the molecular biology of FA have allowed us to investigate the relationship between FA genotype and the nature and severity of the clinical phenotype. Two hundred forty-five patients from all 7 known complementation groups (FA-A to FA-G) were studied. Mutations were detected in one of the cloned FANC genes in 169 patients; in the remainder the complementation group was assigned by cell fusion or Western blotting. A range of qualitative and quantitative clinical parameters was compared for each complementation group and for different classes of mutation. Significant phenotypic differences were found. FA-G patients had more severe cytopenia and a higher incidence of leukemia. Somatic abnormalities were less prevalent in FA-C, but more common in the rare groups FA-D, FA-E, and FA-F. In FA-A, patients homozygous for null mutations had an earlier onset of anemia and a higher incidence of leukemia than those with mutations producing an altered protein. In FA-C, there was a later age of onset of aplastic anemia and fewer somatic abnormalities in patients with the 322delG mutation, but there were more somatic abnormalities in patients with 1VS4 + 4A → T. This study indicates that FA patients with mutations in the FANCG gene and patients homozygous for null mutations in FANCA are high-risk groups with a poor hematologic outcome and should be considered as candidates both for frequent monitoring and early therapeutic intervention.

UR - http://www.scopus.com/inward/record.url?scp=0034672154&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034672154&partnerID=8YFLogxK

M3 - Article

VL - 96

SP - 4064

EP - 4070

JO - Blood

JF - Blood

SN - 0006-4971

IS - 13

ER -